Surface Modification of Mesoporous Silica Nanoparticles for Application in Targeted Delivery Systems of Antitumour Drugs

Overview

Journal Polymers (Basel)

Publisher MDPI

Date 2024 Apr 27

PMID 38675024

Authors

Svetlana Kovtareva

Lyazat Kusepova

Gaukhar Tazhkenova

Togzhan Mashan

Karlygash Bazarbaeva

Eldar Kopishev

Affiliations

Soon will be listed here.

Abstract

The problem of tumour therapy has attracted the attention of many researchers for many decades. One of the promising strategies for the development of new dosage forms to improve oncology treatment efficacy and minimise side effects is the development of nanoparticle-based targeted transport systems for anticancer drugs. Among inorganic nanoparticles, mesoporous silica deserves special attention due to its outstanding surface properties and drug-loading capability. This review analyses the various factors affecting the cytotoxicity, cellular uptake, and biocompatibility of mesoporous silica nanoparticles (MSNs), constituting a key aspect in the development of safe and effective drug delivery systems. Special attention is paid to technological approaches to chemically modifying MSNs to alter their surface properties. The stimuli that regulate drug release from nanoparticles are also discussed, contributing to the effective control of the delivery process in the body. The findings emphasise the importance of modifying MSNs with different surface functional groups, bio-recognisable molecules, and polymers for their potential use in anticancer drug delivery systems.

Citing Articles

Adhesin Antibody-Grafted Mesoporous Silica Nanoparticles Suppress Immune Escape for Treatment of Fungal Systemic Infection.

Cheng M, Liu S, Zhu M, Li M, Yu Q Molecules. 2024; 29(19).

PMID: 39407477 PMC: 11478059. DOI: 10.3390/molecules29194547.

References

Yang B, Ni X, Chen L, Zhang H, Ren P, Feng Y . Honokiol-loaded polymeric nanoparticles: an active targeting drug delivery system for the treatment of nasopharyngeal carcinoma. Drug Deliv. 2017; 24(1):660-669. PMC: 8241046. DOI: 10.1080/10717544.2017.1303854. View

Zhang P, Tang M, Huang Q, Zhao G, Huang N, Zhang X . Combination of 3-methyladenine therapy and Asn-Gly-Arg (NGR)-modified mesoporous silica nanoparticles loaded with temozolomide for glioma therapy in vitro. Biochem Biophys Res Commun. 2019; 509(2):549-556. DOI: 10.1016/j.bbrc.2018.12.158. View

Napierska D, Thomassen L, Rabolli V, Lison D, Gonzalez L, Kirsch-Volders M . Size-dependent cytotoxicity of monodisperse silica nanoparticles in human endothelial cells. Small. 2009; 5(7):846-53. DOI: 10.1002/smll.200800461. View

Zheng Q, Lin T, Wu H, Guo L, Ye P, Hao Y . Mussel-inspired polydopamine coated mesoporous silica nanoparticles as pH-sensitive nanocarriers for controlled release. Int J Pharm. 2014; 463(1):22-6. DOI: 10.1016/j.ijpharm.2013.12.045. View

Keldibekova R, Suleimenova S, Nurgozhina G, Kopishev E . Interpolymer Complexes Based on Cellulose Ethers: Application. Polymers (Basel). 2023; 15(15). PMC: 10422396. DOI: 10.3390/polym15153326. View

Zou Z, He X, He D, Wang K, Qing Z, Yang X . Programmed packaging of mesoporous silica nanocarriers for matrix metalloprotease 2-triggered tumor targeting and release. Biomaterials. 2015; 58:35-45. DOI: 10.1016/j.biomaterials.2015.04.034. View

Hou J, Guo C, Shi Y, Liu E, Dong W, Yu B . A novel high drug loading mussel-inspired polydopamine hybrid nanoparticle as a pH-sensitive vehicle for drug delivery. Int J Pharm. 2017; 533(1):73-83. DOI: 10.1016/j.ijpharm.2017.09.058. View

Bafkary R, Ahmadi S, Fayazi F, Karimi M, Fatahi Y, Ebrahimi S . Amphiphilic hyperbranched polyester coated rod mesoporous silica nanoparticles for pH-responsive doxorubicin delivery. Daru. 2020; 28(1):171-180. PMC: 7214578. DOI: 10.1007/s40199-020-00328-x. View

Song S, Choi J . Enzyme-Responsive Amphiphilic Peptide Nanoparticles for Biocompatible and Efficient Drug Delivery. Pharmaceutics. 2022; 14(1). PMC: 8779831. DOI: 10.3390/pharmaceutics14010143. View

10.

Zhang P, Cao F, Zhang J, Tan Y, Yao S . Temozolomide and chloroquine co-loaded mesoporous silica nanoparticles are effective against glioma. Heliyon. 2023; 9(8):e18490. PMC: 10412909. DOI: 10.1016/j.heliyon.2023.e18490. View

11.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

12.

Shu Y, Song R, Zheng A, Huang J, Chen M, Wang J . Thermo/pH dual-stimuli-responsive drug delivery for chemo-/photothermal therapy monitored by cell imaging. Talanta. 2018; 181:278-285. DOI: 10.1016/j.talanta.2018.01.018. View

13.

Nam H, Kwon S, Chung H, Lee S, Kwon S, Jeon H . Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2009; 135(3):259-67. DOI: 10.1016/j.jconrel.2009.01.018. View

14.

Saini K, Prabhuraj R, Bandyopadhyaya R . Development of Mesoporous Silica Nanoparticles of Tunable Pore Diameter for Superior Gemcitabine Drug Delivery in Pancreatic Cancer Cells. J Nanosci Nanotechnol. 2019; 20(5):3084-3096. DOI: 10.1166/jnn.2020.17381. View

15.

Tu T, Yang S, Tsai M, Wang C, Lee S, Young T . Dual-triggered drug-release vehicles for synergistic cancer therapy. Colloids Surf B Biointerfaces. 2018; 173:788-797. DOI: 10.1016/j.colsurfb.2018.10.043. View

16.

Trendafilova I, Szegedi A, Yoncheva K, Shestakova P, Mihaly J, Ristic A . A pH dependent delivery of mesalazine from polymer coated and drug-loaded SBA-16 systems. Eur J Pharm Sci. 2015; 81:75-81. DOI: 10.1016/j.ejps.2015.10.003. View

17.

Lin J, Liu Z, Zhu Q, Rong X, Liang C, Wang J . Redox-responsive nanocarriers for drug and gene co-delivery based on chitosan derivatives modified mesoporous silica nanoparticles. Colloids Surf B Biointerfaces. 2017; 155:41-50. DOI: 10.1016/j.colsurfb.2017.04.002. View

18.

Meng H, Wang M, Liu H, Liu X, Situ A, Wu B . Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano. 2015; 9(4):3540-57. PMC: 4415452. DOI: 10.1021/acsnano.5b00510. View

19.

Taylor C, Kirby A . Cardiac Side-effects From Breast Cancer Radiotherapy. Clin Oncol (R Coll Radiol). 2015; 27(11):621-9. DOI: 10.1016/j.clon.2015.06.007. View

20.

Watermann A, Brieger J . Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer. Nanomaterials (Basel). 2017; 7(7). PMC: 5535255. DOI: 10.3390/nano7070189. View